Combination therapy before surgery for locally advanced rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of three drugs (serplulimab, CAPOX, and bevacizumab) given before surgery to shrink locally advanced rectal cancer. The goal is to make the tumor easier to remove and potentially improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with locally advanced rectal cancer that has not spread to other parts of the body.
- You have not had any prior cancer treatment (like chemotherapy, radiation, or surgery for this cancer).
- You are healthy enough to undergo surgery after the study treatment.
- You do not have any major bleeding disorders, active infections, or autoimmune diseases.
- You are willing to use effective birth control during the study and for 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of drugs before surgery for locally advanced colorectal cancer. The goal is to see if this treatment shrinks the tumor and improves surgical outcomes.
This trial tests a combination of drugs given before surgery to shrink rectal cancer tumors and improve the chances of successful surgery. The drugs include an immunotherapy called serplulimab, chemotherapy (XELOX), and a targeted therapy called bevacizumab. This approach may help reduce the risk of the cancer coming back.
This trial tests whether giving serplulimab (an immune medicine) plus CAPEOX chemotherapy and celecoxib before surgery can shrink locally advanced rectal cancer and improve outcomes. It may help by increasing immune attack on the tumor while chemotherapy helps reduce the cancer before the operation.
This trial tests whether giving a combination of chemotherapy, radiation, and two newer drugs (an immunotherapy and an anti-angiogenesis drug) before surgery can improve outcomes for people with locally advanced rectal cancer. If you qualify, you would receive this treatment for a few months, and then have surgery.
This trial tests a new approach for advanced low rectal cancer. You'll receive a combination of chemotherapy, immunotherapy, and radiation before surgery, which may help shrink the tumor and make surgery easier.
This trial compares two chemotherapy combinations given before surgery for low rectal cancer. One group gets a standard chemo pill (CAPOX), while the other gets a more intense combination of three chemo drugs plus an immunotherapy drug (PD-1 inhibitor) to see which approach works better at shrinking tumors.
Hear when a new Locally Advanced Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.